A Phase 1 Study of Intraparenchymal Therapy With Irinotecan Hydrochloride Drug-eluting Beads (CM-BC2) as an Adjunct Therapy to Best Standard of Care in Patients With Recurrent, Surgically Resectable Glioblastoma Multiforme.

Trial Profile

A Phase 1 Study of Intraparenchymal Therapy With Irinotecan Hydrochloride Drug-eluting Beads (CM-BC2) as an Adjunct Therapy to Best Standard of Care in Patients With Recurrent, Surgically Resectable Glioblastoma Multiforme.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 03 Aug 2016

At a glance

  • Drugs Irinotecan (Primary)
  • Indications Glioblastoma
  • Focus Adverse reactions
  • Sponsors BTG International
  • Most Recent Events

    • 29 Jul 2016 Status changed from active, no longer recruiting to discontinued due to slow rate of recruitment.
    • 20 Jun 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Jun 2016.
    • 08 Oct 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top